🚀 VC round data is live in beta, check it out!
PolyPid Valuation Multiples
Discover revenue and EBITDA valuation multiples for PolyPid and similar public comparables like Assertio Therapeutics, Lytix Biopharma, Replek, Paradigm Biopharma and more.
PolyPid Overview
About PolyPid
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
Founded
2008
HQ
Employees
60
Website
Sectors
Financials (LTM)
EV
$67M
PolyPid Financials
PolyPid reported last 12-month revenue of —.
In the same LTM period, PolyPid generated — in gross profit and had net loss of ($35M).
Revenue (LTM)
PolyPid P&L
In the most recent fiscal year, PolyPid reported revenue of — and EBITDA of ($32M).
PolyPid expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($32M) | XXX | XXX | XXX |
| Net Profit | ($35M) | XXX | ($34M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PolyPid Stock Performance
PolyPid has current market cap of $77M, and enterprise value of $67M.
Market Cap Evolution
PolyPid's stock price is $4.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $67M | $77M | 0.0% | XXX | XXX | XXX | $-1.79 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPolyPid Valuation Multiples
PolyPid trades at (2.1x) EV/EBITDA.
EV / Revenue (LTM)
PolyPid Financial Valuation Multiples
As of March 21, 2026, PolyPid has market cap of $77M and EV of $67M.
Equity research analysts estimate PolyPid's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PolyPid has a P/E ratio of (2.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $77M | XXX | $77M | XXX | XXX | XXX |
| EV (current) | $67M | XXX | $67M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.1x) | XXX | XXX | XXX |
| EV/EBIT | (2.0x) | XXX | (2.0x) | XXX | XXX | XXX |
| P/E | (2.2x) | XXX | (2.2x) | XXX | XXX | XXX |
| EV/FCF | (2.9x) | XXX | (2.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PolyPid Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PolyPid Margins & Growth Rates
PolyPid's revenue in the last fiscal year grew by —.
PolyPid's revenue per employee in the last FY averaged $0.0M.
PolyPid Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PolyPid Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Assertio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lytix Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Replek | XXX | XXX | XXX | XXX | XXX | XXX |
| Paradigm Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Synthaverse | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PolyPid M&A Activity
PolyPid acquired XXX companies to date.
Last acquisition by PolyPid was on XXXXXXXX, XXXXX. PolyPid acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PolyPid
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPolyPid Investment Activity
PolyPid invested in XXX companies to date.
PolyPid made its latest investment on XXXXXXXX, XXXXX. PolyPid invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PolyPid
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PolyPid
| When was PolyPid founded? | PolyPid was founded in 2008. |
| Where is PolyPid headquartered? | PolyPid is headquartered in Israel. |
| How many employees does PolyPid have? | As of today, PolyPid has over 60 employees. |
| Who is the CEO of PolyPid? | PolyPid's CEO is Dikla Czaczkes Akselbrad. |
| Is PolyPid publicly listed? | Yes, PolyPid is a public company listed on Nasdaq. |
| What is the stock symbol of PolyPid? | PolyPid trades under PYPD ticker. |
| When did PolyPid go public? | PolyPid went public in 2020. |
| Who are competitors of PolyPid? | PolyPid main competitors are Assertio Therapeutics, Lytix Biopharma, Replek, Paradigm Biopharma. |
| What is the current market cap of PolyPid? | PolyPid's current market cap is $77M. |
| Is PolyPid profitable? | No, PolyPid is not profitable. |
| What is the current net income of PolyPid? | PolyPid's last 12 months net income is ($35M). |
| What is the current FCF of PolyPid? | PolyPid's last 12 months FCF is ($23M). |
| What is the current EV/FCF multiple of PolyPid? | Current FCF multiple of PolyPid is (2.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.